Female Infertility Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Female infertility is defined as the inability to achieve a clinical pregnancy after 12 months of regular unprotected sexual intercourse in women under 35 years, or after 6 months in women aged 35 and over. It affects approximately 48 million women worldwide, comprising 37% of all infertility cases. The aetiology is multifactorial, with ovulatory dysfunction (25%), tubal and peritoneal factors (22%), unexplained infertility (28%), and uterine or cervical factors (10%) being the principal categories. In approximately 30–40% of couples, a male factor is identified concurrently.

Female infertility treatment is tailored to the specific cause identified during a structured fertility investigation. Investigations include baseline hormonal profiling (FSH, LH, oestradiol, AMH, prolactin, thyroid function), transvaginal ultrasound for ovarian reserve and uterine anatomy assessment, hysterosalpingography (HSG) or hysteroscopy for tubal and uterine evaluation, and in selected cases, laparoscopy for endometriosis staging and tubal patency assessment. Treatment ranges from ovulation induction with oral medications in anovulatory women to complex assisted reproductive technologies (ART) including in vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI).

Female infertility treatment is time-sensitive, as ovarian reserve (reflected by antral follicle count and AMH level) declines with age—most significantly after age 37. Early referral to a fertility specialist is therefore recommended for women over 35 with any history suggesting reduced fertility, and for all women with known risk factors (irregular cycles, endometriosis, prior pelvic surgery, polycystic ovary syndrome). Emotional support, psychological counselling, and a coordinated multidisciplinary approach are integral to optimising treatment outcomes and patient wellbeing.

Ovulatory dysfunction—including polycystic ovary syndrome (PCOS), hyperprolactinaemia, thyroid disorders, hypothalamic amenorrhoea, and premature ovarian insufficiency (POI)—is treated with targeted medical therapy: clomifene citrate or letrozole for PCOS-related anovulation; dopamine agonists (cabergoline, bromocriptine) for hyperprolactinaemia; thyroid hormone replacement for hypothyroidism; gonadotrophin injections (FSH, LH) for hypogonadotrophic hypogonadism. Tubal factor infertility from post-infective (Chlamydia) tubal damage, endometriosis, or prior surgery is treated with tubal surgery where feasible or, if not, with IVF bypassing the tubes. Endometriosis is managed surgically (laparoscopic excision improving natural conception rates) followed by IVF for moderate-to-severe disease.

Uterine factors including submucosal fibroids (resected hysteroscopically), endometrial polyps, uterine septum (corrected hysteroscopically), intrauterine adhesions (Asherman's syndrome—divided hysteroscopically), and congenital uterine anomalies are addressed surgically before IVF. Diminished ovarian reserve (DOR) is treated with controlled ovarian hyperstimulation and IVF, or with egg donation in women with poor response. Unexplained infertility is typically managed with intrauterine insemination (IUI) with ovarian stimulation for 3–6 cycles before advancing to IVF.

All women who fulfil the clinical definition of infertility (12 months of unprotected intercourse without pregnancy, or 6 months for women over 35) are eligible for fertility investigation and treatment. Women with known fertility risk factors—irregular or absent menstrual cycles, known PCOS or endometriosis, prior pelvic inflammatory disease, prior ectopic pregnancy, or previous cancer treatment—should be referred for assessment earlier. Male partner semen analysis is performed concurrently to identify any concurrent male factor.

Eligibility for specific treatments depends on age, ovarian reserve, partner sperm quality, and uterine and tubal anatomy. IVF is indicated when simpler treatments have failed or are not appropriate. Women with absent or severely depleted ovarian reserve, premature ovarian insufficiency, or failed multiple IVF cycles may consider egg donation or embryo adoption. Medical and lifestyle contraindications to pregnancy should be assessed pre-treatment; women with poorly controlled diabetes, severe hypertension, or significant cardiac disease require pre-conception multidisciplinary optimisation.

First-line treatment for ovulatory dysfunction is oral ovulation induction: letrozole (5 mg on days 2–6; superior to clomifene in PCOS in randomised trials) or clomifene citrate (50–150 mg on days 2–6), with monitoring by transvaginal ultrasound to confirm follicular development and time intercourse or IUI. Gonadotrophin injections (FSH with or without LH) are used for second-line ovulation induction or for controlled ovarian hyperstimulation (COH) in IUI and IVF programmes.

Intrauterine insemination (IUI) deposits washed and concentrated sperm directly into the uterine cavity at the time of ovulation, increasing sperm density at the site of fertilisation. It is indicated for unexplained infertility, mild male factor, or cervical factor, achieving cumulative pregnancy rates of 15–20% per cycle over 3–6 cycles. IVF retrieves multiple mature eggs after COH, fertilises them in the laboratory, and transfers one or two embryos to the uterus 3 or 5 days later. IVF success rates range from 40–50% per cycle in women under 35 to 15–20% per cycle in women aged 40–42. Frozen embryo transfer (FET) allows remaining embryos to be transferred in future cycles, improving cumulative pregnancy rates. Shared decision-making between patient and specialist, guided by current evidence-based clinical guidelines and the patient's individual anatomy, comorbidities, and treatment goals, is essential for selecting the most appropriate treatment modality. Pre-treatment specialist consultation, review of relevant investigations, and multidisciplinary input for complex presentations ensure the best possible outcomes.

Ovulation induction with letrozole achieves clinical pregnancy in 27% of PCOS women per cycle, with cumulative 6-cycle pregnancy rates of 60–70%. IVF achieves live birth rates of 40–50% per cycle in women under 35, representing the most effective treatment for the majority of infertility causes. Cumulative live birth rates after multiple IVF cycles (up to 3–4 cycles) approach 60–80% in appropriately selected patients.

Surgical treatment of endometriosis (laparoscopic excision) improves natural conception rates significantly in women with Stage I–II disease (OR 1.7 compared to no treatment—ESHRE guidelines). Hysteroscopic correction of uterine cavity abnormalities (polyps, septa, fibroids) improves embryo implantation rates in IVF. Egg donation (using donor oocytes) achieves excellent pregnancy rates even in women with severe diminished ovarian reserve or POI, with live birth rates of 45–55% per cycle across age groups, as the key determinant is egg quality (donor age) rather than uterine age.

Ovarian hyperstimulation syndrome (OHSS) is the most serious complication of ovarian stimulation, occurring in 1–2% of IVF cycles as severe OHSS. It is characterised by ovarian enlargement, ascites, pleural effusion, and coagulation abnormalities and requires hospitalisation in severe cases. GnRH antagonist protocols with elective frozen embryo transfer (freeze-all strategy) have significantly reduced severe OHSS rates. Letrozole-based stimulation in IUI carries lower OHSS risk than injectable gonadotrophins.

Multiple pregnancy from twin or higher-order gestation—with significantly increased risks of preterm birth, low birthweight, and maternal complications—is largely preventable by single embryo transfer (SET) in IVF, which is standard practice in most European countries. Ectopic pregnancy risk is slightly higher after IVF (approximately 2–4% versus 1–2% in natural conception). Miscarriage rates in IVF are similar to or slightly higher than natural conception for the same age group—primarily reflecting the age-related increase in chromosomal abnormalities. Preimplantation genetic testing for aneuploidies (PGT-A) selects euploid embryos for transfer, reducing miscarriage rates significantly.

After egg retrieval in IVF, women rest for 24 hours and resume normal activities within 1–2 days. Progesterone supplementation (pessaries, gel, or injection) commences immediately after retrieval and continues until 10–12 weeks gestation if pregnancy is achieved. A pregnancy blood test (serum hCG) is performed 14–16 days after embryo transfer. An early pregnancy ultrasound at 6–7 weeks confirms intrauterine pregnancy and fetal cardiac activity.

Women who achieve pregnancy after IVF are managed by both their fertility clinic and obstetric team, with attention to the higher-risk pregnancy profile associated with IVF (higher pre-eclampsia, small for gestational age risk independent of multiple pregnancy). Women who do not achieve pregnancy after a failed cycle are reviewed by their fertility specialist to assess the cycle response, embryo development, and implantation failure, and to plan subsequent management. Psychological support is offered during and after treatment cycles, recognising the emotional burden of infertility treatment.

IVF in the United States costs USD 12,000–18,000 per cycle including medications (USD 3,000–6,000 separately). Cumulative costs for multiple cycles can exceed USD 40,000–60,000, often without insurance coverage. In the United Kingdom, one NHS IVF cycle is available in some areas for women meeting eligibility criteria; private IVF costs GBP 5,000–8,000 per cycle. Egg donation adds USD 5,000–30,000 for donor compensation in the US.

India is the world's leading destination for affordable IVF, with costs of USD 2,000–4,000 per cycle at accredited fertility centres (Apollo Fertility, Nova IVF, Indira IVF), including all consultations, investigations, stimulation, and embryo transfer. Egg donation costs USD 1,500–4,000 in India. Thailand offers IVF at USD 3,000–6,000, and Spain, Czech Republic, and Cyprus offer popular egg donation programmes for European patients at USD 4,000–8,000. Success rates at leading Indian centres are comparable to European standards, with ICMR-regulated quality standards.

For women with PCOS and anovulation who fail oral ovulation induction, laparoscopic ovarian drilling (LOD)—laparoscopic puncture of multiple follicles in each ovary using diathermy—induces multi-follicle development and normalises LH:FSH ratios. LOD achieves comparable ovulation and pregnancy rates to gonadotrophin injections without the OHSS risk and multiple pregnancy risk. For women with endometriosis-related infertility, laparoscopic excision of endometriosis is preferred over expectant management before ART.

Fertility preservation with embryo or egg cryopreservation allows women facing cancer treatment, surgery, or social egg freezing (planned delay of childbearing) to preserve fertility potential. For women with absolute uterine absence or severe uterine dysfunction, gestational surrogacy (where the intended mother's eggs and the partner's sperm are used to create an embryo transferred to a surrogate carrier) provides a biological parenthood option. Adoption and fostering are important family-building options that should be discussed alongside medical fertility treatments for couples for whom treatment is unsuccessful.